Sanofi

Sanofi reported a series of first-quarter 2022 wins, driven mostly by the success of consumer healthcare (CHC) and the company’s blockbuster Dupixent.

Just like 2016 and the year before, specialty drugs dominate the 2017 list of top performers in the most recent first year after launch class.

The good news … is that innovation is addressing diseases with high-unmet need such as oncology, autoimmune diseases, and central nervous system (CNS) disorders. But, there is a complicating factor in the economic story: the patient population benefiting from launch brands is becoming smaller.

It’s important for the pharma industry to take a closer look at the benefits of going beyond the pill and leveraging technology to deliver better care resulting in better patient outcomes and potential savings to the overall health system.